Linked Life Data

14644405

Source:http://linkedlifedata.com/resource/pubmed/id/14644405

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-12-3
pubmed:abstractText
Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0021-9150
pubmed:author
pubmed:copyrightInfo
Copyright 2003 Elsevier Ireland Ltd.
pubmed:issnType
Print
pubmed:volume
171
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
337-42
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
pubmed:affiliation
Otsuka America Pharmaceutical Inc., Rockville, MD, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Multicenter Study, Clinical Trial, Phase III